Massimo Fantini

Company: Precision Biologics

Job title: Director, Research & Development

Seminars:

Reduction of Circulating Naïve Tregs & gMDSCs Mediated by NEO-201 & Low Levels of Soluble MICA are Prognostic Factors for Efficacy of Combined Treatment With NEO-201 & Pembrolizumab in Adults With Solid Tumours Resistant to Prior Checkpoint Inhibitors 4:30 pm

Examining the Accumulation of immunosuppressive cells in the TME, such as Tregs and gMDSCs is one of the mechanisms of tumour resistance to checkpoint inhibitors Understanding how NEO-201 mediates the killing of targets cells expressing core 1 O-glycans (including cancer cells and immunosuppressive cells) through ADCC and CDC. Elimination of circulating gMDSCs and Tregs mediated…Read more

day: Day Two